Literature DB >> 33895704

Substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues potently inhibit respiratory syncytial virus (RSV) replication and RSV infection-associated inflammatory responses.

Jimin Xu1, Wenzhe Wu2, Haiying Chen1, Yu Xue1, Xiaoyong Bao3, Jia Zhou4.   

Abstract

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in young children, and specific treatment for RSV infections remains unavailable. We herein reported a series of substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues as potent RSV inhibitors. Among them, six low cytotoxic compounds (11, 12, 15, 22, 26, and 28) have been identified and selected to study associated inhibitory mechanisms. All these compounds suppressed not only the viral replication but also RSV-induced IRF3 and NF-κB activation and associated production of cytokines/chemokines. The two most potent compounds (15 and 22) were selected for further molecular mechanism studies associated with their suppression effect on RSV-activated IRF3 and NF-κB. These two compounds decreased RSV-induced IRF3 phosphorylation at serine 396 and p65 phosphorylation at serine 536 at both early and late infection phases. In addition, compound 22 also inhibited RSV-induced p65 phosphorylation at serine 276 at the late phase of RSV infection.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Inflammation; RSV; RSV replication; Salicylamide derivatives

Mesh:

Substances:

Year:  2021        PMID: 33895704      PMCID: PMC8462008          DOI: 10.1016/j.bmc.2021.116157

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.461


  71 in total

1.  Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).

Authors:  Jean-François Bonfanti; Christophe Meyer; Frédéric Doublet; Jérôme Fortin; Philippe Muller; Laurence Queguiner; Tom Gevers; Peggy Janssens; Heidi Szel; Rudy Willebrords; Philip Timmerman; Koen Wuyts; Pieter van Remoortere; Frans Janssens; Piet Wigerinck; Koen Andries
Journal:  J Med Chem       Date:  2008-02-07       Impact factor: 7.446

2.  Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship.

Authors:  Jean-François Bonfanti; Frédéric Doublet; Jérôme Fortin; Jean Lacrampe; Jérôme Guillemont; Philippe Muller; Laurence Queguiner; Eric Arnoult; Tom Gevers; Peggy Janssens; Heidi Szel; Rudy Willebrords; Philip Timmerman; Koen Wuyts; Frans Janssens; Cois Sommen; Piet Wigerinck; Koen Andries
Journal:  J Med Chem       Date:  2007-08-28       Impact factor: 7.446

3.  Organic chemistry. Practical olefin hydroamination with nitroarenes.

Authors:  Jinghan Gui; Chung-Mao Pan; Ying Jin; Tian Qin; Julian C Lo; Bryan J Lee; Steven H Spergel; Michael E Mertzman; William J Pitts; Thomas E La Cruz; Michael A Schmidt; Nitin Darvatkar; Swaminathan R Natarajan; Phil S Baran
Journal:  Science       Date:  2015-05-21       Impact factor: 47.728

Review 4.  Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment.

Authors:  J B Domachowske; H F Rosenberg
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

5.  Human metapneumovirus M2-2 protein inhibits innate cellular signaling by targeting MAVS.

Authors:  Junping Ren; Qingrong Wang; Deepthi Kolli; Deborah J Prusak; Chien-Te K Tseng; Zhijian J Chen; Kui Li; Thomas G Wood; Xiaoyong Bao
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

6.  JMX0207, a Niclosamide Derivative with Improved Pharmacokinetics, Suppresses Zika Virus Infection Both In Vitro and In Vivo.

Authors:  Zhong Li; Jimin Xu; Yuekun Lang; Xiaoyu Fan; Lili Kuo; Lianna D'Brant; Saiyang Hu; Subodh Kumar Samrat; Nicole Trudeau; Anil M Tharappel; Natasha Rugenstein; Cheri A Koetzner; Jing Zhang; Haiying Chen; Laura D Kramer; David Butler; Qing-Yu Zhang; Jia Zhou; Hongmin Li
Journal:  ACS Infect Dis       Date:  2020-09-21       Impact factor: 5.084

Review 7.  Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases.

Authors: 
Journal:  Pediatrics       Date:  1996-01       Impact factor: 7.124

8.  Risk of primary infection and reinfection with respiratory syncytial virus.

Authors:  W P Glezen; L H Taber; A L Frank; J A Kasel
Journal:  Am J Dis Child       Date:  1986-06

Review 9.  Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.

Authors:  Jimin Xu; Pei-Yong Shi; Hongmin Li; Jia Zhou
Journal:  ACS Infect Dis       Date:  2020-03-10       Impact factor: 5.084

Review 10.  Protective and dysregulated T cell immunity in RSV infection.

Authors:  Peter J Openshaw; Christopher Chiu
Journal:  Curr Opin Virol       Date:  2013-06-25       Impact factor: 7.090

View more
  2 in total

1.  Exchange Protein Directly Activated by cAMP 2 Enhances Respiratory Syncytial Virus-Induced Pulmonary Disease in Mice.

Authors:  Junping Ren; Wenzhe Wu; Ke Zhang; Eun-Jin Choi; Pingyuan Wang; Teodora Ivanciuc; Alex Peniche; Youwen Qian; Roberto P Garofalo; Jia Zhou; Xiaoyong Bao
Journal:  Front Immunol       Date:  2021-10-18       Impact factor: 7.561

2.  Monoterpene-Containing Substituted Coumarins as Inhibitors of Respiratory Syncytial Virus (RSV) Replication.

Authors:  Tatyana M Khomenko; Anna A Shtro; Anastasia V Galochkina; Yulia V Nikolaeva; Galina D Petukhova; Sophia S Borisevich; Dina V Korchagina; Konstantin P Volcho; Nariman F Salakhutdinov
Journal:  Molecules       Date:  2021-12-10       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.